Find policies, billing codes, payers, states, and providers
HCPCS Level II J0178: Aflibercept Injection, 1 mg
HCPCS Level II code J0178 denotes a 1 mg dose of aflibercept supplied for injection, commonly used in ophthalmology for intravitreal treatment of retinal vascular disease. Nationally, this code is a key ledger item for tracking drug utilization and cost in outpatient ophthalmic settings where intravitreal injections are performed. It is relevant to payers, providers, and administrators managing specialty drug spend and access for sight-threatening conditions.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what the code represents, clinical context for its use in ophthalmology, and how it maps to the service line of intravitreal pharmacologic therapy. The publication outlines typical sites of service, common billing relationships with procedure codes for intravitreal injection, and payer coverage considerations.
This summary prepares readers to interpret benchmarks and policy updates related to specialty ophthalmic injectables, understand coding relationships for site-of-service billing, and identify the clinical scenarios associated with aflibercept 1 mg without providing clinical recommendations.
Customize your policy alerts
Sign up for hcpcs J0178 policy alerts
Get alerted when payer policies referencing J0178 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J0178 represents the injection of aflibercept, 1 mg. This code is used for billing the administered drug product itself when aflibercept is supplied for injection to treat retinal vascular conditions.
-
Service type: Intravitreal pharmacologic agent administration (drug supply)
-
Typical site of service: Ophthalmology clinic or ambulatory surgical/procedure setting where intravitreal injections are performed
National Reimbursement Benchmarks
National commercial rates for HCPCS J0178 cluster around BUCA’s average commercial rate of $906.40, with several major payers near that midpoint but meaningful variation at the top end. Blue Cross Blue Shield’s median is close to its 25th–75th band around $843.60–$928.40, while Cigna and UnitedHealth Group have medians at $771.60 and similar upper quartiles near $819.00 and $831.90 respectively. Aetna exhibits the broadest spread and highest ceiling, with a 25th percentile at $442.90 and a 75th percentile at $1,724.60, producing a wide interquartile swing.
Measuring dispersion as P75 minus P25 highlights where rates are tightest or widest: Blue Cross Blue Shield’s interquartile range is $90.80, Cigna’s is $47.40, and UnitedHealth Group’s is $60.90, indicating relatively tight clustering. BUCA’s quartiles span $765.80 to $1,012.70 (IQR $246.90), while Aetna’s IQR is $1,281.70, the widest by far and reflecting substantial upper-end leverage compared with other commercial payers.